Aytu BioPharma, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended March 31, 2024 (fiscal 2024 third quarter), filed May 15, 2024. The filing is unaudited. The request’s “2023 Q3” label does not match the period stated in the filing.
Business context
Aytu commercializes prescription pharmaceutical products through its Rx segment and consumer healthcare products through its Consumer Health segment. Its Rx portfolio includes ADHD products Adzenys XR-ODT and Cotempla XR-ODT, as well as pediatric products. The company is winding down Consumer Health, which it says has not generated cash flows, and is focusing on Rx operations and operating cash flow. It is also transitioning ADHD product manufacturing to a third party to improve profitability.
Key financial results
| Metric | Three months ended Mar. 31, 2024 | Nine months ended Mar. 31, 2024 |
|---|---|---|
| Revenue | $18.0 million, down 21% year over year | $63.0 million, down 18% |
| Gross profit / gross margin | $11.7 million / 65%, versus 56% | $42.7 million / 68%, versus 63% |
| Operating loss | $2.5 million | $1.6 million |
| Net loss | $2.9 million, versus $7.2 million | $11.2 million, versus $14.6 million |
| Operating cash flow | Not separately presented for the quarter | Cash used of $0.6 million, versus $14.5 million |
Amounts are in U.S. dollars. For the nine months, Rx revenue was $50.6 million, approximately flat year over year; Consumer Health revenue fell to $12.4 million from $26.2 million. ADHD portfolio revenue grew 42% to $44.0 million, while pediatric portfolio revenue declined to $6.4 million from $18.2 million. The gross-margin improvement reflected the lower share of Consumer Health sales and improved ADHD production efficiencies. Lower operating expenses also contributed to reduced losses.
At March 31, 2024, cash and cash equivalents were $19.8 million; accounts receivable, $29.9 million; current assets, $71.1 million; and current liabilities, $83.7 million. Total assets were $128.9 million and stockholders’ equity was $30.8 million. The balance sheet reported $15.1 million of debt, all classified as current, and a $1.6 million short-term revolving line balance. Cash declined $3.2 million from June 30, 2023. The filing does not present a standalone free-cash-flow measure.
Material changes and unusual items
- Revenue decreased mainly because of the planned Consumer Health wind-down and lower pediatric portfolio sales; ADHD growth partly offset the declines.
- Operating expenses for the nine months declined to $44.3 million from $65.3 million. The comparison includes a $2.6 million impairment in the prior-year period and lower marketing, general and administrative, and research and development costs.
- Derivative warrant remeasurement produced a $5.5 million loss for the nine months, compared with a $6.2 million gain in the prior-year period. These fair-value movements are noncash and materially affect reported net loss.
- The company recorded $1.1 million of income tax expense for the nine months, primarily citing ownership-change limits under Internal Revenue Code Section 382 and existing valuation allowances.
- A $3.8 million Employee Retention Credit receipt remains accrued as a liability; recognition as income depends on management’s reasonable assurance that eligibility requirements have been met, including any regulatory review or clarification.
Liquidity, outlook, and risks
Management states that substantial doubt exists about the company’s ability to continue as a going concern, principally because the $15 million Avenue Capital term loan becomes due January 26, 2025. The debt became current during the quarter. A separate revolving facility has a January 2025 maturity and a $1.6 million outstanding balance. Management expects to refinance the Avenue Note but gives no assurance it can do so. Its plans include improving operating cash flow, winding down Consumer Health, refinancing the note, and, if needed, raising capital or monetizing assets. The filing warns that financing may not be available on acceptable terms and that failure to meet obligations could require curtailing operations or delaying plans.
The 2021 shelf registration had approximately $82.4 million remaining, subject to SEC Form S-3 limitations. The company continues to cite inflation and supply-chain disruption risks. It indefinitely suspended active development of its clinical programs, including AR101; resumption could trigger substantial milestone and royalty obligations. Other disclosed contingencies include product-related payment commitments and pending litigation. A former employee’s employment case remained pending, with a pretrial conference scheduled for June 3, 2024; the company said it could not predict the financial impact. A separate shareholder derivative settlement was subject to court approval.
Management reported effective disclosure controls at reasonable assurance levels and stated that previously identified material weaknesses involving warrant accounting and inventory valuation were remediated as of March 31, 2024, following enhanced procedures, outside expertise, and additional personnel.
Important facts for investors to verify
- Whether Aytu refinances or otherwise repays the $15 million Avenue Note by its January 2025 maturity, and the terms and costs of any refinancing.
- Cash generation after the reported $0.6 million operating cash use, including the effects of working capital and the ERC receipt.
- Progress and costs of the Consumer Health wind-down and the third-party manufacturing transition for ADHD products.
- Whether ADHD growth and improved margins continue, and whether pediatric revenue declines stabilize.
- Potential dilution from outstanding warrants and equity financing, along with noncash warrant valuation changes.
- Resolution of the ERC eligibility review, litigation matters, and contractual or milestone obligations.